Prem S. Shah - Mar 17, 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Co-President of Retail
Signature
/s/ Prem S. Shah
Stock symbol
CVS
Transactions as of
Mar 17, 2022
Transactions value $
-$185,503
Form type
4
Date filed
3/18/2022, 04:55 PM
Previous filing
Mar 1, 2022
Next filing
Mar 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Sale -$180K -1.69K -2.78% $106.65 59.1K Mar 17, 2022 Direct
transaction CVS Common Stock Options Exercise $308K +2.94K +4.97% $104.82 62K Mar 17, 2022 Direct
transaction CVS Common Stock Sale -$313K -2.94K -4.73% $106.65 59.1K Mar 17, 2022 Direct
holding CVS Common Stock (pep) 4.41K Mar 17, 2022 Direct F1
holding CVS Common Stock (restricted) 1.93K Mar 17, 2022 Direct F2
holding CVS Common Stock (restricted) 6.39K Mar 17, 2022 Direct F3
holding CVS Common Stock (restricted) 1.81K Mar 17, 2022 Direct F4
holding CVS Common Stock (restricted) 15.4K Mar 17, 2022 Direct F5
holding CVS Common Stock (restricted) 2.88K Mar 17, 2022 Direct F6
holding CVS ESOP Common Stock 4.54K Mar 17, 2022 Direct
holding CVS Common Stock (restricted) 1.87K Mar 17, 2022 Direct F7
holding CVS Stock Unit (deferred) 5.67K Mar 17, 2022 Direct F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVS Stock Option Options Exercise $0 -2.94K -50% $0.00 2.94K Mar 17, 2022 Common Stock 2.94K $104.82 Direct F9
holding CVS Stock Option 5.35K Mar 17, 2022 Common Stock 5.35K $102.26 Direct F10
holding CVS Stock Option 1.69K Mar 17, 2022 Common Stock 1.69K $62.20 Direct F11
holding CVS Stock Option 12.6K Mar 17, 2022 Common Stock 12.6K $54.19 Direct F12
holding CVS Stock Option 34.3K Mar 17, 2022 Common Stock 34.3K $58.34 Direct F13
holding CVS Stock Option 32.8K Mar 17, 2022 Common Stock 32.8K $74.30 Direct F14
holding CVS Stock Option 26.6K Mar 17, 2022 Common Stock 26.6K $75.24 Direct F15
holding CVS Phantom Stock Credits 11.3K Mar 17, 2022 Common Stock 11.3K $1.00 Direct F16, F17
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of Matching RSUs awarded pursuant to Issuer's Partnership Equity Program, a sub-plan under its ICP, and dividend equivalents on the Matching RSUs. Restrictions lapse on the RSUs on 08/31/2023.
F2 Consists of remaining RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan, a sub-plan under its 2017 ICP. Restrictions lapse in two equal installments commencing on 02/28/2022.
F3 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in four equal installments commencing on 04/01/2022.
F4 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions lapse on 04/01/2022.
F5 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in three equal installments commencing on 04/01/2022.
F6 Consists of RSUs awarded pursuant to Issuer's 2017 ICP. Restrictions on remaining RSUs lapse in two equal installments commencing on 04/01/2022.
F7 Consists of RSUs awarded pursuant to Issuer's Performance-Based Restricted Stock Plan under its 2017 ICP. Restrictions lapse in three equal installments commencing on 02/26/2022.
F8 Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
F9 Option becomes exercisable in four equal installments commencing 04/01/2017.
F10 Option becomes exercisable in four equal installments commencing 04/01/2016.
F11 Option becomes exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
F12 Option becomes exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised.
F13 Option becomes exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
F14 Option becomes exercisable in three equal installments commencing 04/01/2022.
F15 Option vests in three equal installments, on 8/31/2021, 8/31/2022 and 8/31/2023.
F16 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F17 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.